Daily - Oct 20, 2026 v2 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
CHAPTERS
00:00 Biotech Daily Briefing
00:43 RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
01:32 RAP-219 Validates Selective Mechanism in Acute Mania
02:12 Casdatifan Shows Efficacy in Renal Cell Carcinoma
03:02 Casdatifan Delivers 35-Month Median Overall Survival
03:46 Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
04:43 FDA Approves Process 2.0 for Alvotech's SIMLANDI
05:27 Ambrose Acquires AM-Pharma for up to 161 Million Euros
06:16 Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
07:06 Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
07:50 Looking ahead
08:31 SOZO Intuition
SUMMARY
Welcome to today's biotech daily briefing. Today, we lead with positive mid-stage clinical proof-of-concept data from Rapport Therapeutics in acute bipolar mania, expansive platform trial results from Arcus Biosciences evaluating casdatifan across multiple lines of clear cell renal cell carcinoma, and long-term extension data from Teva and Sanofi demonstrating sustained efficacy for duvakitug in inflammatory bowel disease. We also follow regulatory and clinical advancements spanning biomanufacturing, rare disease acquisitions, critical care respiratory medicine, and gastrointestinal oncology. Sources are in the show notes.
CHAPTERS AND SOURCES
00:00 - Biotech Daily Briefing
00:43 - RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
Rapport Therapeutics Reports Positive Phase 2 Results for RAP-219 in Bipolar Mania 2026-10-20:
https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134dex991.htm
PolarityBio Phase 3 COVER DFUS II Meets Primary Endpoint in Diabetic Foot Ulcers 2026-10-20:
https://www.biospace.com/press-releases/polaritybio-highlights-highest-scoring-abstract-award-and-presentation-of-phase-3-cover-dfus-ii-trial-results-at-sawc-fall-2026
01:32 - RAP-219 Validates Selective Mechanism in Acute Mania
02:12 - Casdatifan Shows Efficacy in Renal Cell Carcinoma
Arcus Biosciences Presents ARC-20 Data for Casdatifan Across ccRCC Lines 2026-10-20:
https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/rcus-20261020.htm
03:02 - Casdatifan Delivers 35-Month Median Overall Survival
03:46 - Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
Teva and Sanofi Report 44-Week Phase 2b Data for Duvakitug in IBD 2026-10-20:
https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/UEG-Week-Teva-and-Sanofis-Duvakitug-Maintained-Long-Term-Positive-Outcomes-in-New-Phase-2b-Data-for-Ulcerative-Colitis-and-Crohns-Disease/default.aspx
Odyssey Therapeutics Reports Phase 2a OD-001 Data in Ulcerative Colitis 2026-10-20:
https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-ex99_1.htm
04:43 - FDA Approves Process 2.0 for Alvotech's SIMLANDI
Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process 2026-10-20:
https://www.biospace.com/press-releases/alvotech-receives-fda-approval-for-new-simlandi-manufacturing-process-that-more-than-doubles-output-per-batch
05:27 - Ambrose Acquires AM-Pharma for up to 161 Million Euros
Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million 2026-10-20:
https://www.biospace.com/press-releases/ambrose-healthcare-acquires-am-pharma-for-up-to-161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base
06:16 - Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
Nano24 Reports Positive Phase 2b Results for Inhaled EXO-CD24 in ARDS 2026-10-20:
https://www.businesswire.com/news/home/20261020667516/en/Nano24-Reports-Positive-Phase-2b-Results-for-Inhaled-EXO-CD24-in-Acute-Respiratory-Distress-Syndrome-ARDS-at-the-CHEST-Annual-Meeting-2026
07:06 - Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
Hengrui's Retlirafusp Alfa RELIGHT Phase 3 Results Published in JCO 2026-10-20:
https://www.hengrui.com/media/detail-1054.html
07:50 - Looking ahead
AstraZeneca and Oracle Launch Global AI Collaboration for Clinical Trial Optimisation 2026-10-20:
https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-oracle-launch-global-ai-collaboration-advance-clinical-trial-optimisation-support-better-patient-outcomes.html
Adocia Raises €7 Million and Extends Cash Runway to 2028 2026-10-20:
https://www.adocia.com/composants/uploads/2026/10/ADOCIA-PR-FINANCING-OPERATION-OCTOBER-2026.pdf
08:31 - SOZO Intuition